- Home
- APLM vs MBIO Comparison
APLM vs MBIO Comparison
Compare APLM & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- MBIO
- Stock Information
- Founded
- APLM 2016
- MBIO 2015
- Country
- APLM United States
- MBIO United States
- Employees
- APLM N/A
- MBIO N/A
- Industry
- APLM Blank Checks
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- APLM Finance
- MBIO Health Care
- Exchange
- APLM Nasdaq
- MBIO Nasdaq
- Market Cap
- APLM 6.5M
- MBIO 7.3M
- IPO Year
- APLM N/A
- MBIO N/A
- Fundamental
- Price
- APLM $5.68
- MBIO $1.15
- Analyst Decision
- APLM Strong Buy
- MBIO Strong Buy
- Analyst Count
- APLM 1
- MBIO 1
- Target Price
- APLM $200.00
- MBIO $100.00
- AVG Volume (30 Days)
- APLM 25.0K
- MBIO 1.1M
- Earning Date
- APLM 04-03-2025
- MBIO 05-14-2025
- Dividend Yield
- APLM N/A
- MBIO N/A
- EPS Growth
- APLM N/A
- MBIO N/A
- EPS
- APLM N/A
- MBIO N/A
- Revenue
- APLM $198,000.00
- MBIO N/A
- Revenue This Year
- APLM $415.15
- MBIO N/A
- Revenue Next Year
- APLM N/A
- MBIO N/A
- P/E Ratio
- APLM N/A
- MBIO N/A
- Revenue Growth
- APLM N/A
- MBIO N/A
- 52 Week Low
- APLM $4.71
- MBIO $1.01
- 52 Week High
- APLM $42.00
- MBIO $65.00
- Technical
- Relative Strength Index (RSI)
- APLM 40.12
- MBIO 39.43
- Support Level
- APLM $5.90
- MBIO $1.01
- Resistance Level
- APLM $6.88
- MBIO $1.22
- Average True Range (ATR)
- APLM 0.60
- MBIO 0.09
- MACD
- APLM 0.01
- MBIO 0.03
- Stochastic Oscillator
- APLM 13.17
- MBIO 42.92
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.